Imaging services and cardiac monitoring provider Raytel Medical will go before a Nasdaq panel on February 1 to appeal the stock exchange's decision to delist the San Mateo, CA, company.
The hearing was scheduled after Raytel appealed a decision handed down on September 26 by Nasdaq staff. Nasdaq found that Raytel's common stock had failed to maintain a minimum bid price of $1 a share for a 30-day period, and the market value of the company's public float was less than $5 million during the period.
By AuntMinnie.com staff writersJanuary 2, 2001
Related Reading
Raytel results down amid automation snags, February 14, 2000
Copyright © 2001 AuntMinnie.com
